LONDON (Reuters) – Shares in GSK, Sanofi The companies’ share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug’s withdrawal from markets in 2019 and 2020. The first U.S. trial is expected to start this month.
(Reporting by Natalie Grover in London; Editing by David Goodman)
